Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27


DNA methylation analysis of paediatric low-grade astrocytomas identifies a tumour-specific hypomethylation signature in pilocytic astrocytomas.

Jeyapalan JN, Doctor GT, Jones TA, Alberman SN, Tep A, Haria CM, Schwalbe EC, Morley IC, Hill AA, LeCain M, Ottaviani D, Clifford SC, Qaddoumi I, Tatevossian RG, Ellison DW, Sheer D.

Acta Neuropathol Commun. 2016 May 27;4(1):54. doi: 10.1186/s40478-016-0323-6.


Integrative genome-wide analysis reveals HLP1, a novel RNA-binding protein, regulates plant flowering by targeting alternative polyadenylation.

Zhang Y, Gu L, Hou Y, Wang L, Deng X, Hang R, Chen D, Zhang X, Zhang Y, Liu C, Cao X.

Cell Res. 2015 Jul;25(7):864-76. doi: 10.1038/cr.2015.77.


Effect of the CCND1 A870G polymorphism on prostate cancer risk: a meta-analysis of 3,820 cases and 3,825 controls.

Zheng M, Wan L, He X, Qi X, Liu F, Zhang DH.

World J Surg Oncol. 2015 Feb 15;13:55. doi: 10.1186/s12957-015-0479-8.


Consequence of the tumor-associated conversion to cyclin D1b.

Augello MA, Berman-Booty LD, Carr R 3rd, Yoshida A, Dean JL, Schiewer MJ, Feng FY, Tomlins SA, Gao E, Koch WJ, Benovic JL, Diehl JA, Knudsen KE.

EMBO Mol Med. 2015 Mar 18;7(5):628-47. doi: 10.15252/emmm.201404242.


Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Peyressatre M, Prével C, Pellerano M, Morris MC.

Cancers (Basel). 2015 Jan 23;7(1):179-237. doi: 10.3390/cancers7010179. Review.


Alternative splicing programs in prostate cancer.

Sette C.

Int J Cell Biol. 2013;2013:458727. doi: 10.1155/2013/458727.


On the origins of the androgen receptor low molecular weight species.

Mudryj M, Tepper CG.

Horm Cancer. 2013 Oct;4(5):259-69. doi: 10.1007/s12672-013-0152-z. Review.


Alternative RNA splicing and cancer.

Liu S, Cheng C.

Wiley Interdiscip Rev RNA. 2013 Sep-Oct;4(5):547-66. doi: 10.1002/wrna.1178. Review.


Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.

Lanara Z, Giannopoulou E, Fullen M, Kostantinopoulos E, Nebel JC, Kalofonos HP, Patrinos GP, Pavlidis C.

Hum Genomics. 2013 Jun 5;7:14. doi: 10.1186/1479-7364-7-14.


Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE.

J Clin Invest. 2013 Jan;123(1):493-508. doi: 10.1172/JCI64750.


Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case-control studies.

Yang Y, Wang F, Shi C, Zou Y, Qin H, Ma Y.

PLoS One. 2012;7(5):e36813. doi: 10.1371/journal.pone.0036813. Review.


Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM.

Clin Cancer Res. 2012 Feb 1;18(3):666-77. doi: 10.1158/1078-0432.CCR-11-1867.


Mechanisms and consequences of alternative polyadenylation.

Di Giammartino DC, Nishida K, Manley JL.

Mol Cell. 2011 Sep 16;43(6):853-66. doi: 10.1016/j.molcel.2011.08.017. Review.


Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent.

Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis J, Romkes M, Weissfeld JL.

Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2429-37. doi: 10.1158/1055-9965.EPI-11-0520.


The AR dependent cell cycle: mechanisms and cancer relevance.

Schiewer MJ, Augello MA, Knudsen KE.

Mol Cell Endocrinol. 2012 Apr 16;352(1-2):34-45. doi: 10.1016/j.mce.2011.06.033. Review.


Comprehensive exon array data processing method for quantitative analysis of alternative spliced variants.

Chen P, Lepikhova T, Hu Y, Monni O, Hautaniemi S.

Nucleic Acids Res. 2011 Oct;39(18):e123. doi: 10.1093/nar/gkr513.


Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES.

Endocr Relat Cancer. 2011 Jun;18(3):333-45. doi: 10.1530/ERC-10-0262.


Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function.

Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, Knudsen ES, Jessen WJ, Aronow BJ, Knudsen KE.

J Biol Chem. 2011 Mar 11;286(10):8117-27. doi: 10.1074/jbc.M110.170720.

Items per page

Supplemental Content

Support Center